Infaclav 228.5 is a high-efficacy, broad-spectrum antibiotic combination formulated by Solvista Healthcare. Designed specifically for pediatric use and general infection control, it addresses the growing clinical challenge of bacterial resistance. By combining a potent penicillin-derived antibiotic with a beta-lactamase inhibitor, Infaclav 228.5 provides a robust defense against a wide array of Gram-positive and Gram-negative pathogens.
Composition and Pharmacology
The suspension is a synergistic blend of two critical components:
- Amoxycillin (as Amoxycillin Trihydrate): A semi-synthetic antibiotic that acts by inhibiting the synthesis of bacterial cell walls. It is effective against many bacteria but is susceptible to degradation by beta-lactamase enzymes produced by resistant strains.
- Potassium Clavulanate: This is a “suicide inhibitor” of beta-lactamase. While it has little antibacterial activity on its own, its presence protects Amoxycillin from enzymatic destruction. This allows the Amoxycillin to function effectively even against bacteria that would otherwise be resistant to it.
The “228.5” designation typically refers to the combined strength (often 200mg Amoxycillin + 28.5mg Clavulanate per 5ml), providing a precise ratio optimized for pediatric safety and efficacy.
Therapeutic Indications
Infaclav 228.5 is indicated for the treatment of various bacterial infections where resistance to simple Amoxycillin is suspected or confirmed. Primary clinical applications include:
- Respiratory Tract Infections: Effective against acute otitis media (middle ear infections), sinusitis, tonsillitis, and lower respiratory tract infections like bronchitis and community-acquired pneumonia.
- Urinary Tract Infections (UTI): Treatment of cystitis and urethritis caused by susceptible bacterial strains.
- Skin and Soft Tissue Infections: Management of cellulitis, animal bites, and severe dental abscesses.
- Bone and Joint Infections: Used in specific cases like osteomyelitis where a broad-spectrum approach is required.
Key Product Benefits
Based on the clinical profile and manufacturer highlights, Infaclav 228.5 offers five distinct advantages:
- Broad-Spectrum Antibiotic Coverage: It targets a vast range of bacteria, making it a reliable first-line choice for empirical therapy before specific culture results are available.
- Effectiveness Against Resistant Strains: The addition of Potassium Clavulanate ensures that the medication remains “powerful and reliable” even against beta-lactamase-producing organisms.
- Pediatric-Friendly Formulation: As a dry syrup that is reconstituted into a liquid suspension, it is easy to administer to children who cannot swallow tablets.
- Fast Bacterial Action: It exhibits rapid bactericidal activity, leading to quicker symptomatic relief for the patient.
- Trusted Combination Therapy: Amoxycillin/Clavulanate is a gold-standard combination recognized globally for its safety profile and therapeutic success.
